TORONTO, April 19, 2023 (GLOBE NEWSWIRE) — Dalriada, a leading Canadian contract research organization specializing in small molecule therapies, today announces the appointment of Frosty Loechel, Ph.D. as SVP Biology, Discovery Strategy Group. The appointment validates Dalriada’s commitment to remain at the forefront of small molecule drug discovery expertise and capabilities with its pioneering and agile TURN-KEY™ model.

dr Loechel joins Dalriada from Evotec, where he built a large division first as VP, Metabolic Diseases, and then as SVP, Therapeutic Area Lead and Scientific Director, leading new collaborative drug discovery agreements with pharma/biotech partners and beyond project portfolio strategy in large multi-target cooperations. Previously, Dr. Loechel’s career at Lundbeck, Thermo Fisher, Neurosearch and BioImage.

At Dalriada, Dr. Loechel will be responsible for the scientific strategy in biology for drug discovery programs. With 20 years of academic experience and 25 years of work in pharmaceutical, biotech, and contract research organizations, Dr. Loechel brings a wealth of experience across multiple areas and therapeutic modalities of drug discovery, from target validation to preclinical development. His areas of expertise include in vitro areas of pharmacology, small molecules, CNS and metabolic therapy.

Greeting from Dr. Loechel in the company, Dalriada’s Chief Executive and Co-Founder, Dr. Diana Kraskouskaya commented: “I am pleased that dr. Loechel Dalriada joins. From enabling complex biology to building discovery pipelines and platforms, we strive to be the ultimate partner for our biotech customers. dr Loechel not only brings a wealth of industry experience in small molecule discovery, but more importantly effective strategies to enable innovative discovery programs and bring them to the clinic.”

Prof. Patrick Gunning, co-founder and Chief Scientific Officer of Dalriada added: “Dalriada pioneered its TURN-KEY model in…